The Administrative and Clinical Core administers the MSA PPG. The Principal investigator (PI) is Dr. Low, who will be assisted by Dr. Sid Gilman (Co-PI), who will have a specific focus on administering the Clinical Core.
The specific aims of Core A are to: 1. Provide supervision and direction for the program project as a whole. 2. Maintain appropriate policies and procedures and manuals as required and ensure that all instruments, such as the Unified Multiple System Atrophy Rating Scale (UMSARS), COMPASS, and COMPASS-change are current. 3. Coordinate the conference calls and meetings of the Steering Committee and the conference calls and meetings of Scientific Advisory Committee (SAC). 4. Provide fiscal control for the operations of the program project, including establishment and maintenance of subcontracts and making payments to projects, cores, and enrolling investigators. 5. Monitor recruitment, the timely transfer of data from sites to the Data Core (Core B), the provision of blood samples to the Genetics Core (Core D), interaction of enrolling sites with Project 1 (Gilman), and the transfer of autopsy samples to the Neuropathology Core (Core C) and Project 2 (Benarroch). 6. Liaison with NINDS and provide performance reports to the Performance and Safety Monitoring Board (PSMB) and liaison with the European MSA study Group. A key function is the integration of activities of the 3 cores and 4 projects by facilitating the flow of information between areas. This function has evolved to a high level over the past 4 years and will be further enhanced. Core A will also facilitate interactions with the Steering Committee and Advisory Board. 7. The Clinical Core houses the double-blind placebo controlled study to evaluate if Rifampicin will halt or reverse progression of neurological and autonomic deficits in eariy cases of MSA. This study is housed in this core to emphasize the important core nature of the study, since it brings together the activities of Projects 1, 3, and 4. 8. Liason with Autonomic Rare Disease Research Consortium (U54 NS065736) in the implementation and supervision of the Rifampicin study.
Multiple system atrophy (MSA) is a progressive and fatal disease. Its cause is unknown and treatment is unsatisfactory. This Program Project is specifically devoted to MSA and focuses on the improved diagnosis, improved understanding of its natural history, and an understanding of what causes the disease. This Core administers the PPG and houses an important treatment trial aimed at halting the progression of the disease.
|Loavenbruck, A; Iturrino, J; Singer, W et al. (2015) Disturbances of gastrointestinal transit and autonomic functions in postural orthostatic tachycardia syndrome. Neurogastroenterol Motil 27:92-8|
|Piccione, Ezequiel A; Sletten, David M; Staff, Nathan P et al. (2015) Autonomic system and amyotrophic lateral sclerosis. Muscle Nerve 51:676-9|
|Low, Phillip A; Robertson, David; Gilman, Sid et al. (2014) Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:268-75|
|Wada, Naoki; Singer, Wolfgang; Gehrking, Tonette L et al. (2014) Determination of vagal baroreflex sensitivity in normal subjects. Muscle Nerve 50:535-40|
|Valera, Elvira; Ubhi, Kiren; Mante, Michael et al. (2014) Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy. Glia 62:317-37|
|Ubhi, Kiren; Rockenstein, Edward; Kragh, Christine et al. (2014) Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96. Eur J Neurosci 39:1026-41|
|Overk, Cassia R; Masliah, Eliezer (2014) Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol 88:508-16|
|Figueroa, Juan J; Bott-Kitslaar, Darlene M; Mercado, Joaquin A et al. (2014) Decreased orthostatic adrenergic reactivity in non-dipping postural tachycardia syndrome. Auton Neurosci 185:107-11|
|Mandler, Markus; Valera, Elvira; Rockenstein, Edward et al. (2014) Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol 127:861-79|
|May, Verena E L; Ettle, Benjamin; Poehler, Anne-Maria et al. (2014) ?-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. Neurobiol Aging 35:2357-68|
Showing the most recent 10 out of 108 publications